EyePoint Pharmaceuticals (EYPT) Corporate presentation summary

Strategic focus and market opportunity

• Advancing DURAVYU, a sustained-release tyrosine kinase inhibitor (TKI), for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), targeting a combined $15B+ global market opportunity representing over 80% of the branded retinal market.

• Commercial manufacturing scale-up is underway in a new 41,000 sq ft facility in Northbridge, MA, built to FDA and EMA standards, supporting anticipated NDA filing and U.S. launch.

• Cash and investments of ~$220M provide runway into Q4 2027.

Clinical development and trial progress

• DURAVYU is in Phase 3 trials for both wet AMD (LUGANO and LUCIA) and DME (COMO and CAPRI), with topline wet AMD data expected mid-2026 and full DME enrollment anticipated in 3Q 2026.

• Phase 3 trials are designed as global, randomized, double-masked, aflibercept-controlled studies, following established non-inferiority regulatory pathways.

• Phase 3 wet AMD trials are fully enrolled, with patient-centric designs and endpoints focused on vision maintenance, safety, and reduction in treatment burden.

• DME Phase 3 trials leverage infrastructure from wet AMD studies, with smaller patient numbers for efficient execution.

Product profile and differentiation

• DURAVYU offers multi-mechanism action, inhibiting VEGF, PDGF, and IL-6 pathways, addressing both vascular leakage and inflammation.

• The bioerodible Durasert E insert delivers consistent daily dosing for ≥6 months, with no cold storage required and a favorable safety profile.

• Robust safety and efficacy data from over 190 patients across four clinical trials, with no drug-related severe adverse events.